Skip to main content
eScholarship
Open Access Publications from the University of California

Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.

  • Author(s): Babic, Ana
  • Cramer, Daniel W
  • Kelemen, Linda E
  • Köbel, Martin
  • Steed, Helen
  • Webb, Penelope M
  • Johnatty, Sharon E
  • deFazio, Anna
  • Lambrechts, Diether
  • Goodman, Marc T
  • Heitz, Florian
  • Matsuo, Keitaro
  • Hosono, Satoyo
  • Karlan, Beth Y
  • Jensen, Allan
  • Kjær, Susanne K
  • Goode, Ellen L
  • Pejovic, Tanja
  • Moffitt, Melissa
  • Høgdall, Estrid
  • Høgdall, Claus
  • McNeish, Iain
  • Terry, Kathryn L
  • et al.

Published Web Location

https://link.springer.com/content/pdf/10.1007/s10552-016-0841-3.pdf
No data is associated with this publication.
Abstract

Purpose

Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals.

Methods

We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels.

Results

In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2 was associated with 10% (95% CI 2, 19%) higher CA125 levels, while race (non-white vs. white) was associated with 15% (95% CI 4, 27%) higher CA125 levels.

Conclusion

Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item